Societal CDMO Vlastné imanie 2024

Čo robí Societal CDMO?

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO ist eines der beliebtesten Unternehmen auf Eulerpool.com.